Sentinel lymph node biopsy (SLNB) using radioisotope and blue dye is widely considered the “gold standard” for axillary staging – but does it offer everything we need in increasingly complex breast cancer pathways? Through real-world experience and case-based discussion, the panel will examine the limitations of current practice and show how you could benefit from this more flexible, accurate and patient‑centred approach. The webinar will cover: 1. Key gaps in the current “gold standard” approach 2. Mapping challenges after neoadjuvant treatment 3. The clinical and logistical advantages of delayed SLNB 4. Reducing potential SPIO artifacts with the PostMAG study